Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study

ConclusionThe early combined usage of LHQW and Arbidol may accelerate recovery and improve the prognosis of patients with moderate COVID-19.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

Authors: Schwartz RA, Sharma A, Szepietowski JC, Sandhu S, Goldust M Abstract Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae. There are no Food and Drug Administration specific therapies approved so far; however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially ...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Coronavirus (CoV) outbreaks have recently emerged as a global public health threat due to their exceptional zoonotic potential — a feature arising from their ability to infect a diverse range of potential hosts combined with their high capacity for mutation and recombination. After Severe Acute Respiratory Syndrome (SARS) CoV-1 in 2003 and Middle East Respiratory Syndrome (MERS) CoV in 2012, with the current SARS-CoV-2 pandemic we are now in the midst of the third deadly international CoV outbreak in less than 20 years. Coronavirus outbreaks present a critical threat to global public health and an urgent necessity fo...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) outbreak, called coronavirus disease - 2019 (COVID-19), has affected more than 200 countries across the globe with a higher fatality rate among the ...
Source: Globalization and Health - Category: International Medicine & Public Health Authors: Tags: Research Source Type: research
AbstractNovel SARS ‐CoV‐2 named due to its close homology with severe acute respiratory syndrome coronavirus (SARS‐CoV) is the etiologic agent for the ongoing pandemic outbreak causing loss of life and severe economic burden globally. The virus is believed to be evolved in a recombined form of bat and animal cor onavirus with the capacity to infect human host using the ACE2 receptors as an entry point. Though the disease pathogenesis is not elucidated completely, the virus‐mediated host response retains a similar pattern to that of previous SARS‐CoV. Based on the available trend it is assumed that pedia tric grou...
Source: IUBMB Life - Category: Research Authors: Tags: CRITICAL REVIEW Source Type: research
CONCLUSIONS: Drugs that inhibit viral binding to ACE2 present a strong choice for the current, and if necessary, future outbreaks. Further research is needed to establish the clinical and pharmacological aspects of the identified candidate molecules. PMID: 33015820 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
We present our experience of reorganization of a nuclear medicine service settled in Northern Italy during the pandemic period of March and April 2020 characterized a government-mandated lockdown. Our service remained open during the whole period, performing approximately 80% of the routine practice, while maintaining it COVID-free despite the geographical context characterized by a high risk of infection. Reorganization involved all aspects of a nuclear medicine department, following local, national, and international guidelines for prioritizing patients, telephone and physical triages, deployment of appropriate personal ...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
TriPla Regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 "era". Eur J Ophthalmol. 2020 Oct 07;:1120672120963448 Authors: Sacconi R, Borrelli E, Vella G, Querques L, Prascina F, Zucchiatti I, Bandello F, Querques G Abstract In the last months, a rapidly increasing number of people have been infected with severe acute respiratory syndrome coronavirus 2, the virus causing coronavirus disease 2019 (COVID-19). Due to the risk of cross-infections, the number of visits and injections was dramatically reduced in the last months, and the ...
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). PMID: 33026820 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
In November 2019, a novel coronavirus disease (COVID-19) that causes severe acute respiratory syndrome (SARS)-like symptoms was reported in Wuhan, China. The outbreak has soon declared a pandemic, infecting millions of people and causing nationwide lockdowns in more than 180 countries [1]. Malaysia was one of the countries affected by the pandemic; the first wave of infection starting on January 24, 2020, and the second a month later. On March 18, 2020, the government imposed the Movement Control Order (MCO), which put the country on a partial lockdown [2,3].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
In January of this year, oblivious of the fact that we were about to engage in a twisted round of real-life Jumanji, we released our annual digital health trends e-book. Among one of our 12 forecasts for 2020 was that at-home blood tests would gain traction and become the new direct-to-consumer DNA testing in terms of adoption and availability. While the pandemic threw everyone off guard and messed up regular forecasts, we might have been onto something with our predicted trend. With the need to limit physical contact and trace COVID-positive individuals rapidly, public health authorities worldwide are finding rapid, po...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Future of Pharma Healthcare Design Healthcare Policy fda testing outbreak covid19 at-home tests WHO point-of-care POC antibodies virus nasal swab test PCR Abbot Source Type: blogs
More News: China Health | Coronavirus | COVID-19 | Drugs & Pharmacology | Outbreaks | Pandemics | Respiratory Medicine | SARS | Study